Search research articles
Contact Us
Filters
Showing results (121-130 of 331) with videos related to
Page
of 34
Sort By:
Archives of Internal Medicine
|
September 14, 2011
Pharmaceutical fraud and abuse in the United States, 1996-2010
Zaina P Qureshi, Oliver Sartor, Sudha Xirasagar, et al.
Therapeutic Innovation & Regulatory Science
|
November 16, 2025
Regulatory Requirements for Interchangeable Biosimilar Designation
Praveen J Samy, Morgane C Mouslim, Charles L Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Toxicity and costs of toxicity associated with new cancer drugs: international implications
Terhi Hermanson, LeAnn B Norris, John Bian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2012
Unintended consequences of health information technology: evidence from veterans affairs colorectal cancer oncology watch intervention
John Bian, Charles L Bennett, Deborah A Fisher, et al.
Cancer Treatment and Research
|
November 30, 2022
Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR)
Courtney R Lubaczewski, Nancy F Olivieri, William R Hrushesky, et al.
Expert Opinion on Drug Safety
|
November 17, 2022
Fluoroquinolones: old drugs, putative new toxicities
Cecilia Bove, Robert A Baldock, Oscar Champigneulle, et al.
Expert Opinion on Drug Safety
|
September 23, 2015
Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system
Rasha M Arabyat, Dennis W Raisch, June M McKoy, et al.
The American Journal of Managed Care
|
April 11, 2024
Adjusting starting points for initial price offers: the example of ibrutinib
Jason B Gibbons, Charles L Bennett, Kenneth R Carson, et al.
Expert Opinion on Drug Safety
|
September 11, 2019
An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency
Andrew C Bennett, Charles L Bennett, Bartlett J Witherspoon, et al.
JAMA Ophthalmology
|
May 28, 2013
Vision insurance, eye care visits, and vision impairment among working-age adults in the United States
Yi-Jhen Li, Sudha Xirasagar, Chaiporn Pumkam, et al.
Page
of 34
Search research articles
Search
Showing results (121-130 of 331) with videos related to
Sort By:
Page
of 34
Archives of Internal Medicine
|
September 14, 2011
Pharmaceutical fraud and abuse in the United States, 1996-2010
Zaina P Qureshi, Oliver Sartor, Sudha Xirasagar, et al.
Therapeutic Innovation & Regulatory Science
|
November 16, 2025
Regulatory Requirements for Interchangeable Biosimilar Designation
Praveen J Samy, Morgane C Mouslim, Charles L Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2014
Toxicity and costs of toxicity associated with new cancer drugs: international implications
Terhi Hermanson, LeAnn B Norris, John Bian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2012
Unintended consequences of health information technology: evidence from veterans affairs colorectal cancer oncology watch intervention
John Bian, Charles L Bennett, Deborah A Fisher, et al.
Cancer Treatment and Research
|
November 30, 2022
Consequences to Patients, Clinicians, and Manufacturers When Very Serious Adverse Drug Reactions Are Identified (1997-2019): A Qualitative Analysis from the Southern Network on Adverse Reactions (SONAR)
Courtney R Lubaczewski, Nancy F Olivieri, William R Hrushesky, et al.
Expert Opinion on Drug Safety
|
November 17, 2022
Fluoroquinolones: old drugs, putative new toxicities
Cecilia Bove, Robert A Baldock, Oscar Champigneulle, et al.
Expert Opinion on Drug Safety
|
September 23, 2015
Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system
Rasha M Arabyat, Dennis W Raisch, June M McKoy, et al.
The American Journal of Managed Care
|
April 11, 2024
Adjusting starting points for initial price offers: the example of ibrutinib
Jason B Gibbons, Charles L Bennett, Kenneth R Carson, et al.
Expert Opinion on Drug Safety
|
September 11, 2019
An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency
Andrew C Bennett, Charles L Bennett, Bartlett J Witherspoon, et al.
JAMA Ophthalmology
|
May 28, 2013
Vision insurance, eye care visits, and vision impairment among working-age adults in the United States
Yi-Jhen Li, Sudha Xirasagar, Chaiporn Pumkam, et al.
Page
of 34